Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.44 |
| ▸ | JAK1 | P23458 | 4/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 5/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12442146 | 0.93 | JAK2 (0.47) | JAK2JAK1GRIN2BTYK2JAK3 | |
| SCHEMBL2322562 | 0.91 | SMN1; SMN2 (0.47) | JAK2JAK1GRIN2BTYK2JAK3 | |
| SCHEMBL21050896 | 0.89 | IGF1R (0.50) | IGF1RTNK2 | |
| SCHEMBL21050956 | 0.89 | JAK2 (0.42) | JAK2JAK1KCNK3KCNK9IGF1R | |
| SCHEMBL14654706 | 0.83 | TEC (0.49) | — | |
| SCHEMBL14654694 | 0.83 | TEC (0.49) | — | |
| SCHEMBL14654697 | 0.83 | BTK (0.49) | — | |
| SCHEMBL14654586 | 0.83 | BTK (0.49) | — | |
| SCHEMBL21050808 | 0.81 | IGF1R (0.49) | JAK2JAK1IGF1RSMN1; SMN2TNK2 | |
| SCHEMBL21056239 | 0.81 | JAK2 (0.46) | JAK2JAK1IGF1RGRIN2BTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2534151-B1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2018-11-14 | — | — | EP | disclosed |
| US-8658794-B2 | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof | MERCK SHARP & DOHME B.V. (NL) | 2014-02-25 | — | — | US | disclosed |
| EP-2534151-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | MSD Oss B.V. (NL) | 2012-12-19 | — | — | EP | disclosed |
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2012-12-06 | — | — | US | disclosed |
| WO-2011095556-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | N.V. ORGANON (NL) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309966-A1 | 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS | LCK, ZAP70, FYN | JAK2 155/4885JAK1 121/4885KCNK3 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.